Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Research & Development (2018 - 2025)

Bicycle Therapeutics' Research & Development history spans 8 years, with the latest figure at $51.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 4.0% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $240.3 million, up 38.92%, while the annual FY2025 figure was $240.3 million, 38.92% up from the prior year.
  • Research & Development reached $51.8 million in Q4 2025 per BCYC's latest filing, down from $58.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $71.0 million in Q2 2025 to a low of $9.7 million in Q1 2021.
  • Average Research & Development over 5 years is $34.8 million, with a median of $37.3 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 125.5% in 2023, then increased 0.85% in 2024.
  • A 5-year view of Research & Development shows it stood at $13.0 million in 2021, then soared by 90.79% to $24.7 million in 2022, then surged by 80.82% to $44.7 million in 2023, then grew by 11.37% to $49.8 million in 2024, then grew by 4.0% to $51.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Research & Development are $51.8 million (Q4 2025), $58.4 million (Q3 2025), and $71.0 million (Q2 2025).